C WorldWide Group Holding A S Grows Stake in DexCom, Inc. (NASDAQ:DXCM)

C WorldWide Group Holding A S increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 384,000 shares of the medical device company’s stock after acquiring an additional 12,000 shares during the quarter. DexCom comprises approximately 0.6% of C WorldWide Group Holding A S’s portfolio, making the stock its 20th biggest position. C WorldWide Group Holding A S’s holdings in DexCom were worth $47,651,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Valley National Advisers Inc. lifted its position in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares during the period. MV Capital Management Inc. raised its stake in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after buying an additional 138 shares in the last quarter. Washington Trust Advisors Inc. lifted its holdings in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after buying an additional 193 shares during the period. NBC Securities Inc. purchased a new position in shares of DexCom during the 3rd quarter worth approximately $47,000. Finally, Thompson Siegel & Walmsley LLC bought a new position in shares of DexCom in the 3rd quarter worth approximately $48,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock traded down $13.67 during trading on Friday, hitting $124.34. 8,578,184 shares of the company’s stock traded hands, compared to its average volume of 2,409,208. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The business has a 50-day simple moving average of $131.13 and a 200-day simple moving average of $118.30. The stock has a market capitalization of $49.24 billion, a P/E ratio of 80.22, a PEG ratio of 2.37 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.38%. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. As a group, analysts forecast that DexCom, Inc. will post 1.76 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. Canaccord Genuity Group upped their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Citigroup raised their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Royal Bank of Canada began coverage on DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.67.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock worth $25,530,859 over the last quarter. Company insiders own 0.41% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.